Bristol-myers Squibb Compnay

Ling Li

Michael Matthew Miller

Martin Patrick Allen

Paul Michael Scola

Alaric J Dyckman

Saleem Ahmad

John T Hynes

Li-Qiang Sun

Eric P Gillis

Qian Zhao

Eric Mull

T G Murali Dhar

David R Langley

Hai-Yun Xiao

Claudio Mapelli

John L Gilmore

Hong Wu

Kandhasamy Sarkunam

Michael S Bowsher

Lidet A Negash

Maude A Poirier

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Cyclic peptide immunomodulators

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; Ris &#x2014;OH or &#x2014;OP(O)(OH); L is &#x2014;CR&#x2550;N&#x2014;O&#x2014;CRR&#x2014; or CRR&#x2014;O&#x2014;N&#x2550;CR; Lis a bond, &#x2014;C(O)&#x2014;, or S(O)&#x2014;; and R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Oxime ether compounds

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is &#x2014;CH&#x2014; or &#x2014;C(O)&#x2014;; Ris &#x2014;OH or &#x2014;OP(O)(OH); L is a bond, &#x2014;CH&#x2014;, or &#x2014;C(O)&#x2014;; Ris n-Calkyl; each Ris independently selected from Cl and &#x2014;CH; and n is zero, 1, or 2; provided that if X is &#x2014;CH&#x2014;, then L is &#x2014;CH&#x2014; or &#x2014;C(O)&#x2014;. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Alkylphenyl compounds

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CRor N; Y is CRor N; provided that only one of X and Y is N; (R1) is: or; wherein R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 

Thienopyridines and benzothiophenes useful as IRAK4 inhibitors

Immunomodulators

Growing community of inventors

Pennington, NJ, United States of America

Ling Li